Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH trial of homologous versus heterologous COVID-19 booster vaccination after Janssen priming
NL-OMON52043Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Randomised, single-blind trial of Ad26.COV2.S, tozinameran and elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Erasmus MC. Primary endpoints: SARS-CoV-2 immune response 28 days after second vaccination, Comparison of immune response after single-dose Janssen versus boosted regimens and 2 more. Started Jun 2021; status: recruiting.
02
Drugs
Ad26.COV2.Stozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON52043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52043.